C21, also known as VP01 or "Compound 21," is an agonist of the AT2 receptor currently in development by Vicore Pharma. C21 is being trialed as a drug to treat COVID-19.
C21 is an oral, small molecule drug.
See also
- List of COVID-19 ARB trials - page collecting information on trials of renin-angiotensin system modulating drugs for COVID-19.
